Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

To identify adverse effects of ovulation drugs on pregnancy, including pregnancy loss, fetal teratology and dysmorphology, and infant development up to age 3.

Condition or disease
Infertility

Detailed Description:

This will be an observational cohort trial of the pregnancy of women who conceive in RMN trials, and of their resulting infants through the first 3 years of life.

Study specific procedures will include a patient completed log of prescribed and over the counter medications taken during a normal pregnancy, a review of their pregnancy, delivery, and neonatal records, an exam of the infant within 60 days of birth by a dysmorphologist, and yearly review of infant medical records, growth charts, and a yearly parent administered developmental questionnaire (Ages and Stages) for the first three years of the infant's life.

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Actual Enrollment :	264 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications
Study Start Date :	May 2009
Actual Primary Completion Date :	June 27, 2014
Actual Study Completion Date :	June 27, 2014

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1; Infertile women who conceive spontaneously
2; Infertile women who conceive on various ovulation stimulation medications

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. The relative risks of genetic abnormalities identified at birth and within the first 60 days of life [ Time Frame: 2009 - 2016 ]
2. The relative risk of structural anomalies [ Time Frame: 2009 - 2016 ]
3. The relative risk of cognitive differences [ Time Frame: 2009 - 2016 ]
4. The relative risk of perceived differences of neuro-developmental milestones [ Time Frame: 2009 - 2016 ]

Secondary Outcome Measures :

1. The rate of pregnancy complications, including pregnancy loss [ Time Frame: 2009 - 2016 ]
2. Rates of neonatal and infant medical disorders [ Time Frame: 2009 - 2016 ]
3. Rates of infant growth related to use of letrozole for stimulation of ovulation compared to other treatment modalities for ovulation stimulation, including compared to women who conceive spontaneously. [ Time Frame: 2009 - 2016 ]

Biospecimen Retention:   Samples With DNA

Mothers of newborn infants will be asked to consent to the collection of buccal cells from their infants for DNA testing. Fathers will also be asked to provide buccal cells via buccal swab smears, if blood has not been obtained from them in the course of an RMN trial. The DNA specimens will be available for use in other vetted studies to enable study of independent genetic and environmental factors and gene-environment interactions for a broad range of birth defects and infertility.

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 40 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

The population will include women with infertility who receive ovulation stimulation drugs within the context of a Reproductive Medicine Network sponsored trial as well as their infants.

Criteria

Inclusion Criteria:

• Positive serum hCG within the context of a RMN trial;
• History of infertility meeting female subject entry criteria for a RMN trial;
• Informed consent.

Exclusion Criteria:

• Unable to comply with the demands of the trial.

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States, 35249-7333
United States, California
Stanford University Medical Center
Stanford, California, United States, 94305-5317
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06511
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Wayne State University
Detroit, Michigan, United States, 48201
United States, New Jersey
Hackensack University
Hackensack, New Jersey, United States, 07601
United States, North Carolina
Carolinas Medical Center
Charlotte, North Carolina, United States, 28232-2861
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Pennsylvania State University College of Medicine
Hershey, Pennsylvania, United States, 17033
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78207
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05405

Sponsors and Collaborators

Yale University

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Penn State University

University of Colorado, Denver

University of Michigan

University of Pennsylvania

University of Texas

University of Vermont

Wayne State University

Investigators

Principal Investigator:	Esther Eisenberg, MD, MPH	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Chair:	Nanette Santoro, MD	Albert Einstein College of Medicine, Inc.
Principal Investigator:	Richard Legro, MD	Pennsylvania State University College of Medicine
Study Director:	Robert Brzyski, MD, PhD	The University of Texas Health Science Center at San Antonio
Study Director:	Peter Casson, MD	University of Vermont
Principal Investigator:	Michael Diamond, MD	Wayne State University
Study Director:	Heping Zhang, PhD	Yale University
Study Director:	Gregory Christman, MD	University of Michigan
Study Director:	Christos Coutifaris, MD	University of Pennsylvania
Study Director:	William Schlaff, MD	University of Colorado Denver Health Science Center

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Heping Zhang, Principal Investigator, Yale University
ClinicalTrials.gov Identifier:	NCT00902382 History of Changes
Other Study ID Numbers:	RMN-PregReg; RMN Pregnancy Registry
First Posted:	May 15, 2009
Last Update Posted:	February 7, 2018
Last Verified:	February 2018

Keywords provided by Heping Zhang, Yale University:

Infertility; Ovulation stimulation; Pregnancy

Additional relevant MeSH terms:

Infertility; Genital Diseases, Male; Genital Diseases, Female